Arterial thrombosis in four patients treated with thalidomide

Leukemia and Lymphoma

Volumn 46, Issue 2, 2005, Pages 239-242

  Scarpace, Sarah L ^a   Hahn, Theresa ^b   Roy, Hilary ^b   Brown, Karen ^b   Paplham, Pamela ^b   Chanan Khan, Asher ^b   Van Besien, Koen ^c   McCarthy Jr , Philip L ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Arterial thrombosis; Cerebral vascular accident; Deep vein thrombosis; Multiple myeloma; Non Hodgkin's lymphoma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; CISPLATIN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GEMFIBROZIL; LEVOTHYROXINE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISONE; RITUXIMAB; SERTRALINE; THALIDOMIDE; TISSUE PLASMINOGEN ACTIVATOR; VINCRISTINE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BELOW KNEE AMPUTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOEMBOLISM;

AGED; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; THROMBOSIS; WARFARIN;

EID: 13244256953     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400015675     Document Type: Article

References (17)

1. Clark TE, Edom N, Larson J, Lindsey LJ. A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 2001;24:87-119.
2. Bowcock SJ, Rassam SMB, Ward SM, Turner JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002;7:51-53.
3. Celgene Corporation. Thalomid (thalidomide) and cancer related thromboembolic events. Written communication provided by Medical Services on 3/13/03.
4. Jego C, Barbou F, Laurent P, Gisserot O, Cellarier G, Bonal J, Bouchiat C, Landais C, de Jaureguiberry JP, Dussarat GV. Left atrial thrombus in multiple myeloma treated with thalidomide. (Article in French) Archives des Maladies du Coeur et des Vaisseaux 2003;96:1006-1010.
5. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. Thalidomide and thrombosis. (Article in French) Annales De Dermatologie et de Venereologie (Paris) 2000;127:171-174.
6. Piette JC, Sbai A, Frances C. Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 2002;11:67-70.
7. Pouaha J, Martin S, Trechot P, Barbaud A, Schmutz JL. Thalidomide and thrombosis: three observations. Presse Medicale 2001;30:1008-1009.
8. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clinical Lymphoma 2003;4:32-35.
9. Bennett C, Schumock G, Desai A, Kwaan H, Raisch D, Newlin R. Thalidomide-Associated Deep Vein Thrombosis and Pulmonary Embolism. The American Journal of Medicine 2002;113:603-606.
10. Desai AA, Vogelzang NJ, Raini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal-cell carcinoma. Cancer 2002;95:1029-1035.
11. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. Journal of Thrombosis and Haemostasis 2003;1: 445-449.
12. Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, Valdre L, Palareti G, Masini L, Tura S, Baccarani M. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100:2272-2273.
13. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagulation and Fibrinolysis 2002; 13:187-192.
14. Kaushal V, Kaushal GP, Melkaveri SN, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. Journal of Thrombosis and Haemostasis 2004;2:327-334.
15. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-618.
16. Weber D, Rankin K, Delasalle K, Gavino M, Alexanian R. Thalidomide alone and in combination for previously untreated myeloma. International Multiple Myeloma Workshop, 8th International Conference; 2001.
17. Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Thalidomide in the management of multiple myeloma. Seminars in Hematology 2001;38:250-259.